Oncology Research Pulse
Fostering knowledge exchange across the cancer research community Timely discussions. Expert perspectives. Illuminating the path to progress. Fostering knowledge exchange
Universal
Demystifying North American IRB/EC Requirements for International Research Professionals
Navigating research compliance often means addressing unseen challenges. Explore strategies to identify blind spots and strengthen oversight frameworks.
Single Sign-On Resources
Advarra Single Sign-On (SSO) for user authentication allows users to access all SSO-enabled Advarra products in one place using just one set of credentials.
2025 Survey Report: The State of Site Feasibility
This white paper examines four KPIs most impacting timelines and budgets and offers strategies for effective communication and risk mitigation.
2025 Survey Report: The State of Workforce Development
This white paper examines four KPIs most impacting timelines and budgets and offers strategies for effective communication and risk mitigation.
Logins
Logins Use the links below for logging in to Advarra products and service portals. Advarra’s electronic institutional review board (IRB)
2025: Perspectives and Predictions From Advarra Thought Leaders
2024 has been a year of growth and evolution in clinical research. The coming year is expected to be no
How Your Study’s Informed Consent Can Help Simplify Study Startup
Navigating research compliance often means addressing unseen challenges. Explore strategies to identify blind spots and strengthen oversight frameworks.
Join a Review Committee
REVIEWS Become a Member Join Advarra’s review teams to contribute your expertise to advancing research. Our committees play a vital
Central Oncology Review
Advarra meets the growing needs of oncology by offering robust human subject protections that cancer research institutions expect.
Contact Us
Contact Us We’re here to help you move research forward—faster. Whether you have a question, need support, or want to
The Importance of a Large Network of KOLs for DMCs
In the complex landscape of clinical trials, the data monitoring committee (DMC) serves as the cornerstone at the intersection of